---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-034348"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:26:53.478328+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled

## Summary
- Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.
- Cash and cash equivalents $10.5M at Dec 31, 2022, up from $4.1M at June 30, 2022.
- First patient enrolled in OPMD natural history study in Jan 2023; part of BB-301 program.
- Expects IND/CTA clearance in Q2 2023; first BB-301 dosing anticipated in Q3 2023.
- R&D expenses $3.8M, up $0.7M YoY due to toxicology and manufacturing projects.

## SEC filing metadata
- accession: 0001193125-23-034348
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/0001193125-23-034348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/d375301d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-034348
- JSON: https://secwatch.observer/filing/0001193125-23-034348.json
- Plain text: https://secwatch.observer/filing/0001193125-23-034348.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported financial results for Second Fiscal Quarter ended December 31, 2022.
  - Period: Second Fiscal Quarter ended December 31, 2022
  - Result: reported results
  source text: On February 13, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/0001193125-23-034348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.